Apple Tree Partners / Tokai Pharmaceuticals Tokai Pharmaceuticals / Tokai Pharmaceuticals Inc. / /
Event
FDA Phase / Funding / /
Facility
Dana-Farber Cancer Institute / /
IndustryTerm
treatment of castration-resistant prostate cancer / biopharmaceutical / /
MedicalCondition
cancers / castrationresistant prostate cancer / Advanced Prostate Cancer / castration-resistant prostate cancer / prostate cancer / /
MedicalTreatment
oral therapy / /
Organization
Harvard Medical School / Novartis Venture Fund / Poster Board / Dana-Farber Cancer Institute / /
Person
Jodie Morrison / Mary-Ellen Taplin / /
Position
president and chief executive officer / driver / General / co-principal investigator / professor of medicine / director of genitourinary clinical research / associate professor / /
NEWS RELEASE FOR IMMEDIATE RELEASE New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone in Advanced Prostate Cancer to be Presented at 2014 ASCO GU Symposium CAMBRIDGE, Mass., January 9, 2014 – Tokai Pharm